Boston Scientific Co. (BSX) Expected to Post Earnings of $0.36 Per Share
Wall Street analysts forecast that Boston Scientific Co. (NYSE:BSX) will post earnings of $0.36 per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Boston Scientific’s earnings, with the lowest EPS estimate coming in at $0.35 and the highest estimate coming in at $0.36. Boston Scientific posted earnings of $0.33 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 9.1%. The firm is expected to announce its next quarterly earnings results on Wednesday, April 24th.
On average, analysts expect that Boston Scientific will report full-year earnings of $1.56 per share for the current fiscal year, with EPS estimates ranging from $1.54 to $1.58. For the next financial year, analysts forecast that the firm will post earnings of $1.80 per share, with EPS estimates ranging from $1.72 to $1.88. Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for Boston Scientific.
Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 6th. The medical equipment provider reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.02. The company had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.57 billion. Boston Scientific had a net margin of 17.01% and a return on equity of 25.92%. Boston Scientific’s revenue was up 6.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.34 EPS.
In related news, CFO Daniel J. Brennan sold 22,438 shares of the company’s stock in a transaction that occurred on Thursday, February 14th. The shares were sold at an average price of $39.57, for a total transaction of $887,871.66. Following the sale, the chief financial officer now directly owns 279,183 shares of the company’s stock, valued at approximately $11,047,271.31. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kevin J. Ballinger sold 14,740 shares of the company’s stock in a transaction that occurred on Thursday, January 3rd. The stock was sold at an average price of $33.65, for a total transaction of $496,001.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 361,138 shares of company stock worth $14,316,850. 0.73% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. We Are One Seven LLC purchased a new stake in Boston Scientific during the 4th quarter worth approximately $27,000. Athena Capital Advisors LLC purchased a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $28,000. Ipswich Investment Management Co. Inc. purchased a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $28,000. CWM LLC increased its position in shares of Boston Scientific by 54.3% in the 4th quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 359 shares during the last quarter. Finally, West Oak Capital LLC increased its position in shares of Boston Scientific by 40.0% in the 4th quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 300 shares during the last quarter. 91.89% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Boston Scientific stock traded down $0.35 on Wednesday, reaching $37.49. The company had a trading volume of 4,669,539 shares, compared to its average volume of 7,320,704. The company has a market capitalization of $52.17 billion, a price-to-earnings ratio of 25.50, a price-to-earnings-growth ratio of 2.15 and a beta of 0.88. Boston Scientific has a 52-week low of $26.42 and a 52-week high of $41.00. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.54 and a current ratio of 0.76.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Article: Analyst Ratings Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.